OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience
Aurora Zanghì, Diana Ferraro, Graziella Callari, et al.
Current Neuropharmacology (2023) Vol. 22, Iss. 2, pp. 339-345
Open Access | Times Cited: 9
Aurora Zanghì, Diana Ferraro, Graziella Callari, et al.
Current Neuropharmacology (2023) Vol. 22, Iss. 2, pp. 339-345
Open Access | Times Cited: 9
Showing 9 citing articles:
Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability
Alise Carlson, Moein Amin, Jeffrey A. Cohen
Drugs (2024) Vol. 84, Iss. 3, pp. 285-304
Open Access | Times Cited: 18
Alise Carlson, Moein Amin, Jeffrey A. Cohen
Drugs (2024) Vol. 84, Iss. 3, pp. 285-304
Open Access | Times Cited: 18
Ocrelizumab use in multiple sclerosis: a real-world experience in a changing therapeutic scenario
Lorena Lorefice, Paolo Mellino, Jessica Frau, et al.
Neurological Sciences (2024) Vol. 45, Iss. 8, pp. 3951-3959
Closed Access | Times Cited: 4
Lorena Lorefice, Paolo Mellino, Jessica Frau, et al.
Neurological Sciences (2024) Vol. 45, Iss. 8, pp. 3951-3959
Closed Access | Times Cited: 4
Comparing the efficacy and safety of extended vs standard dosing of ocrelizumab in MS: A systemic review and meta-analysis.
Mirza Mehmood Ali Baig, Fatima Zulfiqar Siddiqui, Anusha Ashkar, et al.
Multiple Sclerosis and Related Disorders (2025) Vol. 94, pp. 106257-106257
Closed Access
Mirza Mehmood Ali Baig, Fatima Zulfiqar Siddiqui, Anusha Ashkar, et al.
Multiple Sclerosis and Related Disorders (2025) Vol. 94, pp. 106257-106257
Closed Access
Clinical and radiological activity after extended interval and standard interval dosing of ocrelizumab in multiple sclerosis: A systematic review and meta-analysis
Mahsa Ghajarzadeh, Mohsen Rastkar, Ellen M Mowry, et al.
Neurological Sciences (2025)
Closed Access
Mahsa Ghajarzadeh, Mohsen Rastkar, Ellen M Mowry, et al.
Neurological Sciences (2025)
Closed Access
De-escalation and Discontinuation of Disease-Modifying Therapies in Multiple Sclerosis
Robert Gross, John R. Corboy
Current Neurology and Neuroscience Reports (2024) Vol. 24, Iss. 9, pp. 341-353
Closed Access | Times Cited: 3
Robert Gross, John R. Corboy
Current Neurology and Neuroscience Reports (2024) Vol. 24, Iss. 9, pp. 341-353
Closed Access | Times Cited: 3
Hypogammaglobulinemia and severe infections in Multiple Sclerosis patients on anti-CD20 agents: a multicentre study
Krzysztof Smolik, Federico Camilli, Ivan Panzera, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 93, pp. 106191-106191
Open Access | Times Cited: 2
Krzysztof Smolik, Federico Camilli, Ivan Panzera, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 93, pp. 106191-106191
Open Access | Times Cited: 2
The cost-utility analysis of adding ocrelizumab to the treatment plan for primary progressive multiple sclerosis in Iran
Ali Darvishi, Ramin Abdi Dezfouli, Zohreh Ghasemian, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2024), pp. 1-10
Closed Access
Ali Darvishi, Ramin Abdi Dezfouli, Zohreh Ghasemian, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2024), pp. 1-10
Closed Access
Parenteral anti-B cell therapy for multiple sclerosis: From origins to the creation of the Russian drug divosilimab
Popova Ev, S. R. Zeynalova
Meditsinskiy sovet = Medical Council (2024), Iss. 12, pp. 108-112
Open Access
Popova Ev, S. R. Zeynalova
Meditsinskiy sovet = Medical Council (2024), Iss. 12, pp. 108-112
Open Access
Strategic De-escalation of Disease-Modifying Therapies in Elderly Patients: Approaches and Considerations
Robert Gross, John R. Corboy
Current Treatment Options in Neurology (2024) Vol. 27, Iss. 1
Closed Access
Robert Gross, John R. Corboy
Current Treatment Options in Neurology (2024) Vol. 27, Iss. 1
Closed Access
